camptothecin has been researched along with cardiovascular agents in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, WP; Chee, GL; Hasinoff, BB; Thampatty, P; Yalowich, JC | 1 |
| Agu, RU; Feridooni, T; Mac Donald, C; Shao, D; Yeung, P | 1 |
2 other study(ies) available for camptothecin and cardiovascular agents
| Article | Year |
|---|---|
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Topics: Animals; Camptothecin; Cardiovascular Agents; Cell Division; CHO Cells; Cricetinae; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Nucleic Acid Synthesis Inhibitors; Razoxane; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1999 |
Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cardiovascular Agents; Cell Death; Cell Line; Cell Survival; Dexrazoxane; Diltiazem; Doxorubicin; Humans; Inhibitory Concentration 50; Irinotecan; Losartan; Myoblasts; Rats | 2013 |